TCE

AvenCell’s platform of T cell engaging bispecific antibody (TCE) is characterized by high-binding affinity to tumor antigens and lower affinity to the CD3 antigen on effector T cells, preventing T cell auto-activation in pre-clinical models.

The use of fully humanized antibodies reduces the risk of immunogenicity even in case of chronic dosing.

AvenCell’s platform of T cell engaging bispecific antibody (TCE) is characterized by high binding affinity to tumor antigens and lower affinity to the CD3 antigen on effector T cells, preventing T cell auto-activation in pre-clinical models. The use of fully humanized antibodies reduces the risk of immunogenicity even in case of chronic dosing. Our lead clinical-stage TCE asset AVC-001 is globally partnered with Bristol-Myers Squibb. AVC-001 is a TCE with binding specificities to CD3 and PSCA, currently in early clinical development in multiple PSCA-positive advanced solid tumors (see https://clinicaltrials.gov/ct2/show/NCT03927573).

GEMoaB TCE Platform Preview 01

Our Patents

As patents are critical to AvenCell’s business, we have filed a wide range of patent applications globally to protect our innovative technologies and products. The patent family is continuously extended.

Andrew Schiermeier, Ph.D.

Chief Executive Officer

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.